Results of cohort analysis on risk of non-fatal congestive cardiac failure and ischaemic heart disease with β2 agonists in the first six months of exposure
| Nedocromil3-150 | Salmeterol | Bambuterol | |
|---|---|---|---|
| Non-fatal cardiac failure | |||
| Number of patients with a report of cardiac failure in first 6 months of exposure | 18 | 45 | 64 |
| Patient-months of exposure | 38265.5 | 64350.4 | 20667.5 |
| Crude overall incidence rate estimates per 1000 patient-months of exposure | 0.47 | 0.70 | 3.10 |
| Crude relative risk (95% CL) | 1 | 1.49 (0.86 to 2.57) | 6.58 (3.90 to 11.10)† |
| Relative risk adjusted for age and sex (95% CL) | 1 | 1.10 (0.63 to 1.91) | 3.41 (1.99 to 5.86)† |
| Relative risk adjusted for age, sex, indication and season of starting treatment (95% CL) | 1 | 0.90 (0.50 to 1.60) | 3.31 (1.91 to 5.71)† |
| Non-fatal ischaemic heart disease | |||
| No. of patients with a report of ischaemic heart disease | 29 | 66 | 26 |
| Patient-months of exposure | 38226.0 | 64308.1 | 20742.4 |
| Crude overall incidence rate estimates per 1000 patient-months of exposure | 0.76 | 1.03 | 1.25 |
| Crude relative risk (95% CL) | 1 | 1.35 (0.87 to 2.09) | 1.65 (0.97 to 2.80) |
| Relative risk adjusted for age and sex (95% CL) | 1 | 1.07 (0.69 to 1.66) | 1.23 (0.73 to 2.08) |
| Relative risk adjusted for age, sex, indication, and season of starting treatment (95% CL) | 1 | 0.94 (0.58 to 1.54) | 1.31 (0.76 to 2.26) |
↵3-150 Reference drug; †p<0.0001.